Community experience with bortezomib in patients with multiple myeloma

American Journal of Hematology

Volumn 82, Issue 7, 2007, Pages 637-639

  Onitilo, Adedayo A ^a   Engel, Jessica ^a   Olatosi, Bankole ^b   Fagbemi, Seth ^a  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bortezomib; Multiple myeloma; Proteasome; Refractory; Relapse

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; BETA 2 MICROGLOBULIN; BORTEZOMIB; CORTICOSTEROID; DNA TOPOISOMERASE INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON; PLATINUM; STEROID; THALIDOMIDE; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; AGING; ALBUMIN BLOOD LEVEL; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMMUNITY CARE; COMORBIDITY; DIARRHEA; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; INFECTION COMPLICATION; KIDNEY FAILURE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BORONIC ACIDS; COMMUNITY MEDICINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SURVIVAL RATE;

EID: 34347350090     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20883     Document Type: Article

References (7)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
3. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
4. Wu KL, van Wieringen W, Vellenga E, Zweegman S, Lokhorst HM, Sonneveld P. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica 2005;90:996-997.
5. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: Phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma. Clin Adv Hematol Oncol 2003;1:190.
6. Chanan-Khan AA, Richardson P, Lonial S, et al. Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis. Blood 2005;106:2550 (abstract).
7. Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103:1195-1200.